---
title: "Thyme Care’s $125M Series E: Oncology Navigation Clears $2B With Payer Capital"
description: "Morgan Health led Thyme Care’s $125M+ Series E above a $2B valuation — Humana, CVS Health Ventures, AlleyCorp, and a16z Bio + Health joined as the company spins up Thyme Companies for biosimilars and trial access."
date: 2026-09-03T00:00:00.000Z
tags: ["2026-vc-news", "startup-funding", "venture-capital", "healthtech", "biotech-life-sciences"]
source: https://venturecapitaltracker.com/2026-thyme-care-125m-series-e-2b-morgan-health
---

# Thyme Care’s $125M Series E: Oncology Navigation Clears $2B With Payer Capital

> Morgan Health led Thyme Care’s $125M+ Series E above a $2B valuation — Humana, CVS Health Ventures, AlleyCorp, and a16z Bio + Health joined as the company spins up Thyme Companies for biosimilars and trial access.

**Morgan Health** led **Thyme Care’s $125 million+** Series E on **September 2, 2026**, taking the Nashville oncology company above a **$2 billion** valuation — roughly **2×** its Series D less than a year earlier (company PR; CNBC).

**Spine:** payer strategics (Humana, CVS Health Ventures) and long-time VC owners ([AlleyCorp](/fund/alleycorp), [a16z Bio + Health](/fund/andreessen-horowitz), [Frist Cressey](/fund/frist-cressey-ventures)) are financing a **platform parent** — Thyme Companies — not just more navigation seats.

## Key facts

| Field | Detail |
| --- | --- |
| Company | [Thyme Care](/startup/thyme-care) (Nashville) |
| Round | **$125M+** Series E |
| Valuation | **>$2B** (company / CNBC) |
| Lead | Morgan Health (JPMorgan) |
| Strategics | Humana; CVS Health Ventures |
| Directory VCs | [AlleyCorp](/fund/alleycorp); [a16z](/fund/andreessen-horowitz); [Frist Cressey](/fund/frist-cressey-ventures) |
| Also | HealthQuest; Foresite; Concord Health Partners; Town Hall Ventures |
| Structure move | New parent **Thyme Companies** for biosimilars + trial accrual businesses |

## Who uses the product — and for what job

**Users:** health plans and employers managing oncology spend; community oncologists in value-based arrangements; patients navigating treatment logistics.

**Job:** fill the gaps that clinics and PBMs leave open — symptom triage, social support, care coordination — so outcomes improve while **total cost of cancer care** falls. CNBC frames the product as a virtual navigation platform; the company positions Thyme Box as the operating system for that work.

This is **payer-aligned oncology operations**, not a consumer wellness app.

## Why now

- Series D (~$97M, Fierce) was less than a year ago — the double to **>$2B** signals commercial proof, not a seed-story rebrand.
- Drug affordability, biosimilar uptake, and trial enrollment remain structural bottlenecks; Thyme Companies is the explicit bet that navigation data can spawn adjacent businesses.
- Strategics Humana and CVS sitting next to Morgan Health is the distribution thesis in capital form.

## Why these funds — portfolio fit

| Investor | Likely fit |
| --- | --- |
| Morgan Health | JPMorgan’s healthcare investing arm underwriting **payer-grade** cost/quality evidence |
| Humana / CVS Health Ventures | Buyers who can embed navigation into plan and retail-health channels |
| [AlleyCorp](/fund/alleycorp) | Long-cycle healthcare operator capital; returning owner from earlier rounds |
| [a16z Bio + Health](/fund/andreessen-horowitz) | Continuity from Series B thesis — oncology VBC as a category, not a feature |
| [Frist Cressey](/fund/frist-cressey-ventures) | Healthcare services / provider-adjacent growth |

**Likely founder rationale:** raise from the **payers who write the checks for cancer care**, then keep multi-stage VCs who already know the unit economics — not a cold growth-equity auction.

*Morgan Health, Humana, CVS Health Ventures, Foresite, Town Hall, HealthQuest, and Concord are covered editorially without inventing `/fund/` pages.*

## Competitive map

| Layer | Players | Difference |
| --- | --- | --- |
| Specialty VBC navigation | Thyme Care | Oncology-only; payer risk alignment |
| Primary-care VBC | Oak Street / agilon-style models | Different specialty economics |
| Incumbent nav / PBM services | Health-system and PBM teams | Often less tech-native; harder to productize across markets |

## What is not proven

- Exact post-money figure above “more than $2B” is not broken out.
- Revenue, membership counts, and medical-cost savings vs control are **not disclosed** in the Series E release.
- Thyme Companies’ first business is **expected** later in 2026 — not live.

## Practical takeaway

- **Founders (health):** A Series E with Morgan Health + Humana + CVS is a **distribution financing**, not a vanity round — show payer-ready outcomes.
- **Investors:** Underwrite whether Thyme Companies dilutes focus or compounds a data moat.
- **Operators / journalists:** The story is parent-entity expansion into **biosimilars and trials**, not another “AI care chat” headline.

### Sources

1. [PR Newswire — Thyme Care Series E](https://www.prnewswire.com/news-releases/thyme-care-closes-125-million-series-e-establishes-thyme-companies-to-broaden-its-impact-across-the-oncology-ecosystem-302867835.html)
2. [CNBC — $2B+ valuation](https://www.cnbc.com/2026/09/02/thyme-care-raises-125-million-cancer-startups-value-over-2-billion.html)
3. [Fierce Healthcare](https://www.fiercehealthcare.com/health-tech/oncology-company-thyme-care-raises-125m-backed-morgan-health-humana-and-cvs-health)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.